Hydronephrosis Treatment

Global Hydronephrosis Treatment Market to Reach US$3.8 Billion by 2030

The global market for Hydronephrosis Treatment estimated at US$2.5 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. Unilateral Hydronephrosis Type, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the Bilateral Hydronephrosis Type segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$686.4 Million While China is Forecast to Grow at 11.4% CAGR

The Hydronephrosis Treatment market in the U.S. is estimated at US$686.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$810.7 Million by the year 2030 trailing a CAGR of 11.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Hydronephrosis Treatment Market – Key Trends & Drivers Summarized

Why Is the Demand for Hydronephrosis Treatment Increasing Worldwide?

Hydronephrosis, the swelling of one or both kidneys due to urine buildup, is becoming increasingly common across various demographics due to rising incidences of kidney stones, urinary tract infections (UTIs), congenital urinary tract abnormalities, and age-related urological issues. The growing global prevalence of these underlying causes, especially among aging populations and individuals with chronic health conditions like diabetes and hypertension, is significantly increasing the need for effective hydronephrosis diagnosis and treatment. Neonatal screening programs are also detecting congenital hydronephrosis more frequently, contributing to early intervention and the demand for pediatric treatment options. Patients experiencing pain, infection, or compromised kidney function due to obstruction of the urinary flow require timely intervention—ranging from medication and catheterization to surgical correction. The rise in awareness about kidney health, advancements in imaging technologies, and the integration of urological services into primary care are all leading to earlier diagnosis and treatment, fueling growth in the global hydronephrosis treatment market.

How Are Technological and Surgical Innovations Improving Hydronephrosis Management?

Technological advancements are reshaping the landscape of hydronephrosis treatment, offering more precise, minimally invasive, and patient-centric solutions. Imaging technologies such as high-resolution ultrasonography, CT urography, and magnetic resonance urography (MRU) are playing a critical role in early detection and accurate assessment of urinary tract obstructions. On the therapeutic side, endoscopic and laparoscopic surgical techniques have dramatically improved patient outcomes by enabling less invasive procedures with quicker recovery times, reduced postoperative pain, and lower complication rates. For instance, percutaneous nephrostomy, ureteral stenting, and pyeloplasty—either open or robotic-assisted—have become standard interventions for managing severe cases. Robotic surgery, in particular, has revolutionized complex reconstructive procedures, especially in pediatric and repeat-surgery scenarios, by offering higher precision and fewer complications. Furthermore, innovations in drug therapy, such as targeted antibiotics for infection control and alpha-blockers to aid urine flow in certain cases, are enhancing non-surgical treatment effectiveness. These medical and surgical advances are making hydronephrosis treatment safer, faster, and more personalized, broadening the market scope.

What Role Do Healthcare Policies and Diagnostics Access Play in Market Growth?

Healthcare access and public health policies have a direct impact on the diagnosis and treatment of hydronephrosis, especially in emerging economies where late diagnosis often results in more advanced disease states. Governments and health organizations are increasingly promoting routine screening for at-risk populations, including newborns, pregnant women (to detect fetal hydronephrosis), and older adults with a history of urological disorders. Improvements in healthcare infrastructure—such as the availability of diagnostic imaging in rural and underserved areas—are also contributing to earlier detection and management. Insurance coverage and reimbursement policies for advanced imaging and surgical interventions are critical factors influencing treatment uptake in both public and private healthcare systems. Additionally, national urology guidelines and increased awareness campaigns about the signs and consequences of untreated hydronephrosis are driving patients to seek earlier medical consultation. As diagnostic capabilities expand and healthcare systems improve their ability to provide timely urologic care, more patients are receiving interventions at earlier stages of the disease, further propelling market growth.

What Are the Key Drivers of Growth in the Hydronephrosis Treatment Market?

The growth in the hydronephrosis treatment market is driven by multiple interconnected factors, including an aging population, increasing prevalence of causative urological conditions, advancements in diagnostics and surgery, and expanding access to specialized healthcare. First, the global increase in elderly populations—who are more prone to urinary tract obstructions, enlarged prostates, and kidney dysfunction—has significantly raised the incidence of hydronephrosis and the demand for urological care. Second, the rising burden of lifestyle-related diseases such as obesity, diabetes, and hypertension is contributing to secondary complications that lead to kidney swelling. Third, continual innovation in minimally invasive surgical techniques and medical imaging is making hydronephrosis treatment more effective and accessible. Fourth, public health efforts to integrate urological screening into primary care, along with better patient education, are leading to earlier diagnosis and intervention. Lastly, the emergence of advanced healthcare delivery systems in developing countries—supported by investments in medical infrastructure and insurance penetration—is expanding the patient base for hydronephrosis care. Together, these trends are driving robust growth in the hydronephrosis treatment market, with a focus on faster, safer, and more targeted care strategies across all age groups.

SCOPE OF STUDY:

The report analyzes the Hydronephrosis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Unilateral Hydronephrosis Type, Bilateral Hydronephrosis Type); Indication (Intrinsic Indication, Extrinsic Indication); Diagnosis (Laboratory Tests Diagnosis, Imaging Diagnosis); Treatment (Shock Wave Lithotripsy Treatment, Laparoscopy Treatment, Bladder Catheterization Treatment, Steroid Therapy Treatment, Other treatment types); Age Group (Adult, Pediatric)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• 3M Company
• AbbVie Inc.
• Allergan
• Amgen Inc.
• Anthem Bio Pharm
• B. Braun Melsungen AG
• Boston Scientific Corporation
• Coloplast A/S
• Cook Medical
• F. Hoffmann-La Roche Ltd
• Karl Storz SE & Co. KG
• Medtronic plc
• NephroGenex, Inc.
• Novartis AG
• Olympus Corporation
• PHRAXIS, INC.
• Sanofi
• Siemens Healthineers AG
• Stryker Corporation
• Teleflex Incorporated

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.